Krystal Biotech/$KRYS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Krystal Biotech
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Ticker
$KRYS
Sector
Primary listing
Employees
295
Headquarters
Website
Krystal Biotech Metrics
BasicAdvanced
$7.7B
38.27
$6.84
0.48
-
Price and volume
Market cap
$7.7B
Beta
0.48
52-week high
$298.30
52-week low
$122.80
Average daily volume
324K
Financial strength
Current ratio
9.953
Quick ratio
9.279
Long term debt to equity
0.621
Total debt to equity
0.766
Profitability
EBITDA (TTM)
162.919
Gross margin (TTM)
94.08%
Net profit margin (TTM)
52.64%
Operating margin (TTM)
41.45%
Effective tax rate (TTM)
-8.11%
Revenue per employee (TTM)
$1,320,000
Management effectiveness
Return on assets (TTM)
8.44%
Return on equity (TTM)
18.91%
Valuation
Price to earnings (TTM)
38.275
Price to revenue (TTM)
19.473
Price to book
6.27
Price to tangible book (TTM)
6.27
Price to free cash flow (TTM)
40.111
Free cash flow yield (TTM)
2.49%
Free cash flow per share (TTM)
6.527
Growth
Revenue change (TTM)
33.94%
Earnings per share change (TTM)
128.00%
3-year earnings per share growth (CAGR)
7.60%
What the Analysts think about Krystal Biotech
Analyst ratings (Buy, Hold, Sell) for Krystal Biotech stock.
Krystal Biotech Financial Performance
Revenues and expenses
Krystal Biotech Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Krystal Biotech stock?
Krystal Biotech (KRYS) has a market cap of $7.7B as of February 21, 2026.
What is the P/E ratio for Krystal Biotech stock?
The price to earnings (P/E) ratio for Krystal Biotech (KRYS) stock is 38.27 as of February 21, 2026.
Does Krystal Biotech stock pay dividends?
No, Krystal Biotech (KRYS) stock does not pay dividends to its shareholders as of February 21, 2026.
When is the next Krystal Biotech dividend payment date?
Krystal Biotech (KRYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Krystal Biotech?
Krystal Biotech (KRYS) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.